¸ð½Ã´Â±Û ÇÁ·Î±×·¥ ÃÊ·ÏÁ¢¼ö »çÀüµî·Ï ¹ßÇ¥ÀÚ ¾È³» ¼ö»óÀÚ ¾È³» Çà»çÀå¾È³» ¼÷¹Ú¾È³» Ȩ
 ÃÖ¿ì¼ö Æ÷½ºÅÍ»ó
2014³âµµ Á¦ 100Â÷ ´ëÇÑ»êºÎÀΰúÇÐȸ ÃÖ¿ì¼ö Æ÷½ºÅÍ»ó ¼ö»óÀÚ·Î ¼±Á¤µÇ½ÉÀ» Áø½ÉÀ¸·Î ÃàÇϵ帳´Ï´Ù.
¸ðüžÆÀÇÇÐ
  • ¼º¸í : Â÷ÇöÈ­
  • ¼Ò¼Ó : °æºÏÀÇ´ë
  • ³í¹®Á¦¸ñ : The upper cutoff values of 50-g glucose challenge test that can omit 100-g glucose tolerance test according to
                   NDDG and Carpenter and Coustan criteria
ºÎÀÎÁ¾¾çÇÐ
  • ¼º¸í : ¹éÀ̼±
  • ¼Ò¼Ó : ¼º±Õ°üÀÇ´ë
  • ³í¹®Á¦¸ñ : Survival analysis of Revised 2013 FIGO Staging Classification of Epithelial Ovarian Cancer and Comparison with
                   Previous FIGO Staging Classification
»ý½Ä³»ºÐºñÇÐ
  • ¼º¸í : ±è¼ö¹Ì
  • ¼Ò¼Ó : °¡Å縯ÀÇ´ë
  • ³í¹®Á¦¸ñ : The expression of Mullerian Inhibiting Substance Type II Receptor (MISRII) in Endometrial hyperplasia
ÀϹݺÎÀΰúÇÐ
  • ¼º¸í : ÀÌÁö¼±
  • ¼Ò¼Ó : ¾ÆÁÖÀÇ´ë
  • ³í¹®Á¦¸ñ : Lateral distribution of ovarian endometriomas and postoperative recurrences